TY - JOUR
T1 - Urine Leukotriene E4
T2 - Implications as a Biomarker in Chronic Rhinosinusitis
AU - Choby, Garret
AU - Low, Christopher M.
AU - Levy, Joshua M.
AU - Stokken, Janalee K.
AU - Pinheiro-Neto, Carlos
AU - Bartemes, Kathy
AU - Marino, Michael
AU - Han, Joseph K.
AU - Divekar, Rohit
AU - O’Brien, Erin K.
AU - Lal, Devyani
N1 - Publisher Copyright:
© American Academy of Otolaryngology–Head and Neck Surgery Foundation 2021.
PY - 2022/2
Y1 - 2022/2
N2 - Objective: To provide a comprehensive state-of-the-art review of the emerging role of urine leukotriene E4 (uLTE4) as a biomarker in the diagnosis of chronic rhinosinusitis (CRS), aspirin-exacerbated respiratory disease (AERD), and asthma. Data Sources: Ovid MEDLINE(R), Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Review Methods: A state-of-the-art review was performed investigating the role of uLTE4 as a diagnostic biomarker, predictor of disease severity, and potential marker of selected therapeutic efficacy. Conclusions: uLTE4 has been shown to be a reliable and clinically relevant biomarker for CRS, AERD, and asthma. uLTE4 is helpful in ongoing efforts to better endotype patients with CRS and to predict disease severity. Implications for Practice: Aside from being a diagnostic biomarker, uLTE4 is also able to differentiate aspirin-tolerant patients from patients with AERD and has been associated with objective disease severity in patients with CRS with nasal polyposis. uLTE4 levels have also been shown to predict response to medical therapy, particularly leukotriene-modifying agents.
AB - Objective: To provide a comprehensive state-of-the-art review of the emerging role of urine leukotriene E4 (uLTE4) as a biomarker in the diagnosis of chronic rhinosinusitis (CRS), aspirin-exacerbated respiratory disease (AERD), and asthma. Data Sources: Ovid MEDLINE(R), Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, and Scopus. Review Methods: A state-of-the-art review was performed investigating the role of uLTE4 as a diagnostic biomarker, predictor of disease severity, and potential marker of selected therapeutic efficacy. Conclusions: uLTE4 has been shown to be a reliable and clinically relevant biomarker for CRS, AERD, and asthma. uLTE4 is helpful in ongoing efforts to better endotype patients with CRS and to predict disease severity. Implications for Practice: Aside from being a diagnostic biomarker, uLTE4 is also able to differentiate aspirin-tolerant patients from patients with AERD and has been associated with objective disease severity in patients with CRS with nasal polyposis. uLTE4 levels have also been shown to predict response to medical therapy, particularly leukotriene-modifying agents.
KW - AERD
KW - aspirin-exacerbated respiratory disease
KW - biomarker
KW - chronic rhinosinusitis
KW - endotype
KW - nasal polyps
KW - phenotype
KW - uLTE4
KW - urine leukotriene E4
UR - http://www.scopus.com/inward/record.url?scp=85105939442&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105939442&partnerID=8YFLogxK
U2 - 10.1177/01945998211011060
DO - 10.1177/01945998211011060
M3 - Review article
C2 - 33973823
AN - SCOPUS:85105939442
SN - 0194-5998
VL - 166
SP - 224
EP - 232
JO - Otolaryngology - Head and Neck Surgery (United States)
JF - Otolaryngology - Head and Neck Surgery (United States)
IS - 2
ER -